

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**RemeGen Co., Ltd.\***

**榮昌生物製藥(煙台)股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 9995)**

## **ANNOUNCEMENT ON THE RESIGNATION OF AN EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”) of RemeGen Co., Ltd.\* (the “**Company**”) has recently received the written resignation from Dr. He Ruyi, an executive Director. Due to personal career development, Dr. He Ruyi has tendered his resignation as an executive Director of the second session of the Board, as a member of the strategy committee of the Board and as the chief strategic officer of the Company, and will cease to be a core technical personnel of the Company. Following his resignation, Dr. He Ruyi will no longer hold any position in the Company. Dr. He Ruyi has confirmed that he has no disagreement with the Company, the Board and the management of the Company, and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company.

According to the relevant provisions under the Company Law of the People's Republic of China (《中華人民共和國公司法》), the Self-Regulatory Guideline for Listed Companies on the Science and Technology Innovation Board of the Shanghai Stock Exchange No. 1 — Regularization of Operation (《上海證券交易所科創板上市公司自律監管指引第 1 號—規範運作》), the articles of association of the Company and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, the resignation of Dr. He Ruyi would not result in the number of members of the Board being less than the minimum quorum, would not affect the normal operation of the Board and would not have an adverse impact on the daily operation of the Company. The resignation report of Dr. He Ruyi shall take effect upon its delivery to the Board (i.e. February 6, 2025). The Company will complete the by-election of director(s) in accordance with statutory procedures as soon as practicable.

During his tenure of service as an executive Director, Dr. He Ruyi was dedicated to his duties, diligent and responsible. The Company and the Board would like to express their sincere gratitude to Dr. He Ruyi for his contributions to the Company during his tenure of service.

By order of the Board  
**RemeGen Co., Ltd.\***  
**Mr. Wang Weidong**  
*Chairman and executive director*

Yantai, The People's Republic of China  
February 6, 2025

*As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin and Mr. Lin Jian as the executive Directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive Directors, and Mr. Hao Xianjing, Mr. Chen Yunjin and Mr. Huang Guobin as the independent non-executive Directors.*

\* *For identification purpose only*